Follow the Neuphoria Therapeutics Inc. share price and the full insider trade history of the company, a listed equity based in United States. Shares trade on the US market, under the oversight of SEC (Form 4). The latest transaction was filed on 23 October 2025 (Acquisition). Among the most active insiders: Lynx1 Capital Management LP. The full history is accessible without an account.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
1 of 1 declaration
Neuphoria Therapeutics Inc. is a company focused on developing innovative treatments for neurological disorders. It is listed on the XNAS market.